Multiple Sclerosis

To determine whether newly developed treatments are safe and effective, physician-scientists rely on clinical trials. These studies are not only important research tools; they also provide patients with access to experimental therapies not yet widely available.

Because technologies and therapeutic options are continually developing, the OMRF Multiple Sclerosis Center uses clinical trials as one way of delivering cutting-edge treatments to our patients. Of course, participating in clinical trials is optional. But many choose to enroll to receive new therapies and improve standards of care for individuals with MS. Patients also receive medication, laboratory and diagnostic procedures, and intensive medical evaluation and assessment—all at no cost.

Patients may also participate in our MS Center Registry and Repository. This unique research tool allows individuals with MS to provide clinical information and samples to help our physician-scientists better understand this complicated disease.

Clinical research is proving that with comprehensive disease management, we can impact the course of the disease, achieve normal or near-normal life expectancy, reduce the potential for significant disability, and improve quality of life.

For more information on any of our studies, call (405) 271-6241 or email Micki-moore@omrf.org.

CURRENTLY ENROLLING:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis. (ASCEND)

A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis